Related references
Note: Only part of the references are listed.Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy
Susan O'Brien et al.
BLOOD (2008)
Disappearance of pre-existing high HHV-6 DNA load in blood after allogeneic SCT
P. Hubacek et al.
BONE MARROW TRANSPLANTATION (2007)
Transmission of integrated human herpesvirus-6 in allogeneic hematopoietic stem cell transplantation
R. T. Kamble et al.
BONE MARROW TRANSPLANTATION (2007)
Dendritic cell vaccination in allogeneic stem cell recipients: Induction of human cytomegalovirus (HCMV)-specific cytotoxic T lymphocyte responses even in patients receiving a transplant from an HCMV-seronegative donor
Goetz Ulrich Grigoleit et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Laboratory diagnosis of cytomegalovirus infection and disease in immunocompromised patients
W. Lawrence Drew
CURRENT OPINION IN INFECTIOUS DISEASES (2007)
Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation
A. Busca et al.
TRANSPLANT INFECTIOUS DISEASE (2007)
Human herpesvirus 7 in pediatric hematopoietic stem cell transplantation
Muhammad Khanani et al.
PEDIATRIC BLOOD & CANCER (2007)
Human herpesvirus 6 DNA levels in cerebrospinal fluid due to primary infection differ from those due to chromosomal viral integration and have implications for diagnosis of encephalitis
Katherine N. Ward et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2007)
Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab
Winnie W. Cheung et al.
AMERICAN JOURNAL OF HEMATOLOGY (2007)
Epidemiologic analysis of reactivated cytomegalovirus antigenernia in patients with cancer
Xiang Y. Han
JOURNAL OF CLINICAL MICROBIOLOGY (2007)
Leflunomide failure to control recurrent cytomegalovirus infection in the setting of renal failure after allogeneic stem cell transplantation
M. Battiwalla et al.
TRANSPLANT INFECTIOUS DISEASE (2007)
The prevalence of chromosomally integrated human herpesvirus 6 genomes in the blood of UK blood donors
Hoe Nam Leong et al.
JOURNAL OF MEDICAL VIROLOGY (2007)
Human herpesvirus 6 and central nervous system disease in hematopoietic cell transplantation
Danielle M. Zerr
JOURNAL OF CLINICAL VIROLOGY (2006)
An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab
Giuseppe Visani et al.
LEUKEMIA & LYMPHOMA (2006)
Human herpesvirus-6 infection in solid organ and stem cell transplant recipients
Per Ljungman et al.
JOURNAL OF CLINICAL VIROLOGY (2006)
Transmission of human herpesvirus 8 by blood transfusion
Wolfgang Hladik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Evaluation of the COBAS Amplicor HCMV Monitor for early detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation
C. Lengerke et al.
BONE MARROW TRANSPLANTATION (2006)
Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract
DJ Winston et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation
E Ayala et al.
BONE MARROW TRANSPLANTATION (2006)
Treatment of refractory CMV-infection following hematopoietic stem cell transplantation with the combination of foscarnet and leflunomide
K. Ehlert et al.
KLINISCHE PADIATRIE (2006)
Human herpesvirus 6 chromosomal integration in immunocompetent patients results in high levels of viral DNA in blood, sera, and hair follicles
KN Ward et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2006)
Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients
PLJ van der Heiden et al.
BONE MARROW TRANSPLANTATION (2006)
Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation
H Einsele et al.
BLOOD (2006)
Transmission of integrated human herpesvirus 6 through stem cell transplantation: Implications for laboratory diagnosis
DA Clark et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Treatment of multidrug-resistant cytomegalovirus retinitis with systemically administered leflunomide
ME Levi et al.
TRANSPLANT INFECTIOUS DISEASE (2006)
The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo
SJF Kaptein et al.
ANTIVIRAL RESEARCH (2006)
Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab
KA Thursky et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Cidofovir for cytomegalovirus reactivation in pediatric patients after hematopoietic stem cell transplantation
S Cesaro et al.
JOURNAL OF CLINICAL VIROLOGY (2005)
Unexpected occasional persistence of high levels of HHV-6 DNA in sera: Detection of variants A and B
KN Ward et al.
JOURNAL OF MEDICAL VIROLOGY (2005)
Quantitative detection and differentiation of human herpesvirus 6 subtypes in bone marrow transplant patients by using a single real-time polymerase chain reaction assay
S Reddy et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2005)
Human herpesviruses-6 and-7 each cause significant neurological morbidity in Britain and Ireland
KN Ward et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2005)
Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival
P Moreton et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation
DM Zerr et al.
CLINICAL INFECTIOUS DISEASES (2005)
Cytomegalovirus disease before hematopoietic cell transplantation as a risk for complications after transplantation
BC Fries et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2005)
A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients
FM Mattes et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy
M Boeckh et al.
BLOOD (2004)
Efficacy and tolerability of Alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia -: Change of regimen needed?
K Rieger et al.
LEUKEMIA & LYMPHOMA (2004)
Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and-DRB1 genomically identical volunteers?
O Ringdén et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2004)
Human herpesvirus 6 (HHV-6) is transmitted from parent to child in an integrated form and characterization of cases with chromosomally integrated HHV-6 DNA
K Tanaka-Taya et al.
JOURNAL OF MEDICAL VIROLOGY (2004)
Use of leflunomide in an allogeneic bone marrow transplant recipient with refractory cytomegalovirus infection
RK Avery et al.
BONE MARROW TRANSPLANTATION (2004)
A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL)
C Nabhan et al.
LEUKEMIA & LYMPHOMA (2004)
Guidelines on the diagnosis and management of chronic lymphocytic leukaemia
D Oscier et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megatile analysis
P Ljungman et al.
BLOOD (2003)
Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation
M Hakki et al.
BLOOD (2003)
Bone marrow failure associated with herpesvirus 8 infection in a patient undergoing autologous peripheral blood stem cell transplantation
M Cuzzola et al.
CLINICAL INFECTIOUS DISEASES (2003)
Human herpesvirus 7-associated meningitis and optic neuritis in a patient after allogeneic stem cell transplantation
T Yoshikawa et al.
JOURNAL OF MEDICAL VIROLOGY (2003)
Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding pre-emptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial
G Gerna et al.
BLOOD (2003)
Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products
KG Nichols et al.
BLOOD (2003)
Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation
DJ Winston et al.
CLINICAL INFECTIOUS DISEASES (2003)
Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity
M Boeckh et al.
BLOOD (2003)
Human herpesvirus (HHV)-6 and HHV-7: Two closely related viruses with different infection profiles in stem cell transplantation recipients
D Boutolleau et al.
JOURNAL OF INFECTIOUS DISEASES (2003)
Human herpesvirus-7 infection of the CNS with acute myelitis in an adult bone marrow recipient
KN Ward et al.
BONE MARROW TRANSPLANTATION (2002)
Evaluation of the specificity and sensitivity of indirect immunofluorescence tests for IgG to human herpesviruses-6 and-7
KN Ward et al.
JOURNAL OF VIROLOGICAL METHODS (2002)
Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: Contrasting results between recipients of grafts from related and unrelated donors
E Meijer et al.
CLINICAL INFECTIOUS DISEASES (2002)
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
J Lundin et al.
BLOOD (2002)
Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy
H Einsele et al.
BLOOD (2002)
Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors
P Ljungman et al.
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES (2002)
Definitions of cytomegalovirus infection and disease in transplant recipients
P Ljungman et al.
CLINICAL INFECTIOUS DISEASES (2002)
Human herpesvirus 6 viremia in bone marrow transplant recipients: clinical features and risk factors
T Yoshikawa et al.
JOURNAL OF INFECTIOUS DISEASES (2002)
Infections post transplant - Ganciclovir is effective for prophylaxis and treatment of human herpesvirus-6 in allogeneic stem cell transplantation
S Tokimasa et al.
BONE MARROW TRANSPLANTATION (2002)
Case report: Human herpesvirus 7 associated fatal encephalitis in a peripheral blood stem cell transplant recipient
PKS Chan et al.
JOURNAL OF MEDICAL VIROLOGY (2002)
Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation
P Reusser et al.
BLOOD (2002)
Effect of antivirals on human herpesvirus 6 replication in hematopoietic stem cell transplant recipients
DM Zerr et al.
CLINICAL INFECTIOUS DISEASES (2002)
Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age
C Kollman et al.
BLOOD (2001)
Human herpesvirus 6 reactivation and encephalitis in allogeneic bone marrow transplant recipients
DM Zerr et al.
CLINICAL INFECTIOUS DISEASES (2001)
Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers
S Szmania et al.
BLOOD (2001)
Evaluation of the Murex CMV DNA Hybrid Capture assay (version 2.0) for early diagnosis of cytomegalovirus infection in recipients of an allogeneic stem cell transplant
H Hebart et al.
BONE MARROW TRANSPLANTATION (2001)
Successful preemptive cidofovir treatment for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation
U Platzbecker et al.
TRANSPLANTATION (2001)
Cytomegalovirus pneumonia in adults with leukemia: An emerging problem
Q Nguyen et al.
CLINICAL INFECTIOUS DISEASES (2001)
Rising pp65 antigenemia during preemptive anticytomegalovinus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes
WG Nichols et al.
BLOOD (2001)
Cytomegalovirus (CMV) DNA load in plasma for the diagnosis of CMV disease before engraftment in hematopoietic stem-cell transplant recipients
AP Limaye et al.
JOURNAL OF INFECTIOUS DISEASES (2001)
Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients
P Ljungman et al.
BLOOD (2001)
Virological, clinical, and ophthalmologic features of cytomegalovirus retinitis after hematopoietic stem cell transplantation
F Crippa et al.
CLINICAL INFECTIOUS DISEASES (2001)
Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis
C Craddock et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients
P Ljungman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Bone marrow failure associated with human herpesvirus 8 infection after transplantation
M Luppi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
CMV pneumonia in allogeneic BMT recipients undergoing early treatment or pre-emptive ganciclovir therapy
CM Machado et al.
BONE MARROW TRANSPLANTATION (2000)
Human herpesvirus-6 antigenemia after liver transplantation
I Lautenschlager et al.
TRANSPLANTATION (2000)
Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation
VC Emery et al.
LANCET (2000)
Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection
H Einsele et al.
BONE MARROW TRANSPLANTATION (2000)
Suppressive effects of human herpesvirus-6 on thrombopoietin-inducible megakaryocytic colony formation in vitro
H Isomura et al.
JOURNAL OF GENERAL VIROLOGY (2000)
Share Paper
